139 related articles for article (PubMed ID: 9805817)
21. Natural compounds containing a catechol group enhance the formation of Nε-(carboxymethyl)lysine of the Maillard reaction.
Fujiwara Y; Kiyota N; Tsurushima K; Yoshitomi M; Mera K; Sakashita N; Takeya M; Ikeda T; Araki T; Nohara T; Nagai R
Free Radic Biol Med; 2011 Apr; 50(7):883-91. PubMed ID: 21195168
[TBL] [Abstract][Full Text] [Related]
22. Relative quantification of N(epsilon)-(Carboxymethyl)lysine, imidazolone A, and the Amadori product in glycated lysozyme by MALDI-TOF mass spectrometry.
Kislinger T; Humeny A; Peich CC; Zhang X; Niwa T; Pischetsrieder M; Becker CM
J Agric Food Chem; 2003 Jan; 51(1):51-7. PubMed ID: 12502384
[TBL] [Abstract][Full Text] [Related]
23. [Importance of advanced glycation end products--AGE products].
Jakus V; Cársky J; Hrnciarová M
Bratisl Lek Listy; 1998 Jul; 99(7):368-75. PubMed ID: 9748727
[TBL] [Abstract][Full Text] [Related]
24. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication.
Niwa T
J Chromatogr B Biomed Sci Appl; 1999 Aug; 731(1):23-36. PubMed ID: 10491986
[TBL] [Abstract][Full Text] [Related]
25. [Advanced glycation end products (AGEs), free radicals and diabetes].
Gillery P
J Soc Biol; 2001; 195(4):387-90. PubMed ID: 11938555
[TBL] [Abstract][Full Text] [Related]
26. The Maillard reaction inhibitors and their biological and therapeutic significance.
Sztanke K; Pasternak K
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):156-8. PubMed ID: 15323184
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
28. Age-related accumulation of Maillard reaction products in human articular cartilage collagen.
Verzijl N; DeGroot J; Oldehinkel E; Bank RA; Thorpe SR; Baynes JW; Bayliss MT; Bijlsma JW; Lafeber FP; Tekoppele JM
Biochem J; 2000 Sep; 350 Pt 2(Pt 2):381-7. PubMed ID: 10947951
[TBL] [Abstract][Full Text] [Related]
29. [Advanced glycation end products: A risk factor for human health].
Wautier MP; Tessier FJ; Wautier JL
Ann Pharm Fr; 2014 Nov; 72(6):400-8. PubMed ID: 25438650
[TBL] [Abstract][Full Text] [Related]
30. The significance of the products of the Maillard (browning) reaction in diabetes.
Dominiczak MH
Diabet Med; 1991 Jul; 8(6):505-16. PubMed ID: 1832349
[TBL] [Abstract][Full Text] [Related]
31. The ABC of the diabetic hand--advanced glycosylation end products, browning and collagen.
Isdale AH
Br J Rheumatol; 1993 Oct; 32(10):859-61. PubMed ID: 8401994
[No Abstract] [Full Text] [Related]
32. Presence of 3-deoxyglucosone, a potent protein crosslinking intermediate of Maillard reaction, in diabetic serum.
Niwa T; Takeda N; Yoshizumi H; Tatematsu A; Ohara M; Tomiyama S; Niimura K
Biochem Biophys Res Commun; 1993 Oct; 196(2):837-43. PubMed ID: 8240359
[TBL] [Abstract][Full Text] [Related]
33. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes.
Peyroux J; Sternberg M
Pathol Biol (Paris); 2006 Sep; 54(7):405-19. PubMed ID: 16978799
[TBL] [Abstract][Full Text] [Related]
34. Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging.
Obeid R; Shannan B; Herrmann W
Med Hypotheses; 2011 Nov; 77(5):884-8. PubMed ID: 21880434
[TBL] [Abstract][Full Text] [Related]
35. Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.
Aldini G; Vistoli G; Stefek M; Chondrogianni N; Grune T; Sereikaite J; Sadowska-Bartosz I; Bartosz G
Free Radic Res; 2013 Aug; 47 Suppl 1():93-137. PubMed ID: 23560617
[TBL] [Abstract][Full Text] [Related]
36. The Maillard or browning reaction in diabetes.
John WG; Lamb EJ
Eye (Lond); 1993; 7 ( Pt 2)():230-7. PubMed ID: 7607341
[No Abstract] [Full Text] [Related]
37. [Role of advanced glycosylation end products in the pathogenesis of hypertension].
Zukowska-Szczechowska E; Tomaszewski M; Grzeszczak W
Przegl Lek; 2003; 60(9):585-7. PubMed ID: 15065338
[TBL] [Abstract][Full Text] [Related]
38. [Advanced glycosylation end products and chronic complications of diabetes mellitus].
Méndez JD
Gac Med Mex; 2003; 139(1):49-55. PubMed ID: 12666409
[TBL] [Abstract][Full Text] [Related]
39. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs.
Chuyen NV
Mol Nutr Food Res; 2006 Dec; 50(12):1140-9. PubMed ID: 17131455
[TBL] [Abstract][Full Text] [Related]
40. [Biochemical properties and clinical significance of protein glycation products].
Staniszewska M; Gamian A
Postepy Hig Med Dosw; 2003; 57(2):123-47. PubMed ID: 12866352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
